Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease

NCT00169923 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

200

Enrollment

OTHER

Sponsor class

Stopped it was not possible to recruit any patient in the study

Conditions

Chronic Kidney Disease
Inflammation

Interventions

DRUG: rosiglitazone

Sponsor

Leiden University Medical Center